Evidence map›Paper›PMID 41023031›Full record

ArticleScientific reports2025

Adaptive immune responses associated with the progression of premalignant lesions to colorectal cancer.

Zhishan Chen, Dongwoo Kim, Jifeng Wang, Qiongyi Huang, Yaohui Gao, Jiayi Zheng, Linshuoshuo Lyu, Yinying Li, Ling Lu, Ruting Xie and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Zhishan Chen *Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Dongwoo Kim *Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, 15355, Republic of Korea.
Jifeng Wang *Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Qiongyi HuangDepartment of Pathology, Shanghai Tenth People's Hospital Affiliated to Tongji University, Shanghai, 200072, China.
Yaohui GaoDepartment of Pathology, Shanghai Tenth People's Hospital Affiliated to Tongji University, Shanghai, 200072, China.
Jiayi ZhengDepartment of Pathology, Shanghai Tenth People's Hospital Affiliated to Tongji University, Shanghai, 200072, China.
Linshuoshuo LyuDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Yinying LiDepartment of Pathology, Shanghai Tenth People's Hospital Affiliated to Tongji University, Shanghai, 200072, China.
Ling LuDepartment of Pathology, Shanghai Tenth People's Hospital Affiliated to Tongji University, Shanghai, 200072, China.
Ruting XieDepartment of Pathology, Shanghai Tenth People's Hospital Affiliated to Tongji University, Shanghai, 200072, China.
Jung Sun KimDivision of Oncology/Hematology, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, 15355, Republic of Korea.
Ah-Reum LimDivision of Oncology/Hematology, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, 15355, Republic of Korea.
Se Ryeon LeeDivision of Oncology/Hematology, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, 15355, Republic of Korea.
Jinny ParkDivision of Oncology/Hematology, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, 15355, Republic of Korea.
Hwa Jung SungDivision of Oncology/Hematology, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, 15355, Republic of Korea.
Dongyan HanDepartment of Pathology, Shanghai Tenth People's Hospital Affiliated to Tongji University, Shanghai, 200072, China. han_dongyan@163.com.
Xingyi GuoDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA. xingyi.guo@vumc.org.ORCID http://orcid.org/0000-0001-5269-1294
Jungyoon ChoiDivision of Oncology/Hematology, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, 15355, Republic of Korea. choijy1905@gmail.com.ORCID http://orcid.org/0000-0001-9534-0400

Funding

Transcriptome-wide association study to identify susceptibility genes for colorectal cancerR37CA227130 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GUO, XINGYI · 2018 to 2023
$3.7M
National Research Foundation of Korea RS-2023-00210034NCI NIH HHS R37CA227130
6 · The paper itself

Abstract

Immune response during the progression of premalignant lesions and their molecular subtype to colorectal cancer (CRC) remains unclear. Using gene expression data from 135 normal (NLs), 176 conventional adenomas (AD), 42 serrated polyps (SER), and 2760 CRC samples, we estimated overall immune activity (ImmuneScore) and tumor-infiltrating lymphocyte (TIL) abundance using the xCell tool. We evaluated association of the ImmuneScore and TILs with CRC progression using adjusted multivariable regression models. Immunohistochemistry (IHC) staining for five immunological markers was conducted on NL, early- and late-stage AD, and carcinoma tissues from 75 study participants. The consensus molecular subtypes (CMS) of adenomas and carcinomas were classified using random forest methods, and the association of immune activity with CRC progression was assessed. Immune activity consistently decreased from NLs through premalignant lesions to adenocarcinoma, more prominently in AD than SER (AD vs. NL: odds ratio = 0.86, 95% CI = 0.84‒0.88; SER vs. NL: 0.89, 0.85‒0.93). Similar patterns were observed in B cells, CD4 + effector memory T cells, CD8 + naïve T cells, and CD8 + cytotoxic T cells. IHC staining of these immunological markers verified their roles in CRC progression. Our analysis revealed that CMS3 is a major subtype of AD. Consistently, higher immune activity was observed in premalignant lesions than in CRCs of the CMS3 subtype. This study provides additional insights into alterations in immune response and their important role in CRC premalignant lesion progression and subtypes.

Indexed as

Adaptive ImmunityColorectal NeoplasmsPrecancerous ConditionsAdenomaAgedDisease ProgressionFemaleHumansLymphocytes, Tumor-InfiltratingMaleMiddle AgedAdaptive immune responseColorectal cancerConventional adenomaPremalignant lesionsSerrated polyps

Identifiers

PMID41023031
PMCPMC12480846

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.